[Role of bone gammagraphy in the diagnosis of secondary osteomalacia in a patient treated with tenofovir].
It is reported a HIV infected patient under antiretroviral therapy including tenofovir therapy who was referred to the Nuclear Medicine Department to complete bone pain study. A bone scan was performed at 3 hours after the injection of 740 MBq of 99mTc-MDP, revealing an abnormal distribution with characteristic changes compatible with osteomalacia. In further analysis, a secondary hyperparathyroidism and osteomalacia were diagnosed in the context of Fanconi syndrome, an infrequent complication described in patients under treatment with tenofovir.
Torres Isidro
M V
MV
Servicio de Medicina Nuclear, Hospital Carlos III, Madrid. mv_torres@hotmail.com
García Benayas
T
T
del Val Gómez Martínez
M
M
González Gallardo
F
F
Gambí Pisonero
N
N
Castilla Miguel
S
S
González-Lahoz
J
J
Gallego Sanz
D
D
D000225:Adenine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D003404:Creatinine / Q000097:blood; D005198:Fanconi Syndrome / Q000097:blood / Q000139:chemically induced*; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000139:chemically induced / Q000000981:diagnostic imaging*; D061466:Lopinavir; D008297:Male; D063065:Organophosphonates / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D010018:Osteomalacia / Q000139:chemically induced / Q000000981:diagnostic imaging*; D011744:Pyrimidinones / Q000008:administration & dosage / Q000627:therapeutic use; D011877:Radionuclide Imaging; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D019438:Ritonavir / Q000008:administration & dosage / Q000627:therapeutic use; D000068698:Tenofovir
D019380:Anti-HIV Agents; D063065:Organophosphonates; D011744:Pyrimidinones; D018894:Reverse Transcriptase Inhibitors; D061466:Lopinavir; D000068698:Tenofovir; D003404:Creatinine; D000469:Alkaline Phosphatase; D000225:Adenine; D019438:Ritonavir